Using hydrogel organoids to study African-American lymphomas and their treatment
Hydrogel-based Organoids of African-American Lymphomas to Study B Cell Receptor Pathway Inhibitors
This study is looking at how non-Hodgkin's lymphoma affects younger African-American patients and aims to find better treatments by creating mini-tumors in the lab to see how certain drugs can help improve their care.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Georgia Institute of Technology NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-10899668 on NIH RePORTER |
What this research studies
This research investigates the molecular mechanisms of non-Hodgkin's lymphoma, particularly focusing on African-American patients who are diagnosed at a younger age and have poorer outcomes. By creating hydrogel-based organoids that mimic the tumor environment, researchers aim to explore how B cell receptor pathway inhibitors can be used to improve treatment responses. The study will analyze genetic alterations specific to African-American lymphomas to better understand their unique challenges and treatment needs. Patients may benefit from insights that could lead to more effective, tailored therapies for this population.
Who could benefit from this research
Good fit: Ideal candidates for this research are African-American individuals diagnosed with diffuse large B-cell lymphoma or marginal zone lymphomas.
Not a fit: Patients with lymphomas who do not identify as African-American may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies specifically designed for African-American patients with lymphomas.
How similar studies have performed: Previous research has shown promising results in understanding genetic variations in lymphomas, but this specific approach using hydrogel organoids is relatively novel.
Where this research is happening
Atlanta, United States
- Georgia Institute of Technology — Atlanta, United States (Active)
Researchers
- Principal investigator: Singh, Ankur — Georgia Institute of Technology
- Study coordinator: Singh, Ankur
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.